Invectys well poised to bring its anti-HLA-G CAR-T cells to clinical trials …
Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research With an extended Phase I and a new delivery method…
Invectys focuses on the development of innovative anti-cancer therapeutic approaches in immunotherapy. It is backed by French and international private investors…
Invectys élu « meilleur projet – jeune entreprise » 2019 par le Board international de MATWIN Invectys, société biopharmaceutique développant des thérapies…
Invectys will attend to the 18th annual BIO€QUITY Europe Meet Invectys there ! More information: invest@invectys.com 18TH ANNUAL BIO€QUITY EUROPE Bio€quity…
BIO-Europe Spring 2019 March 25th – 27th 2019 Messe Wien Exhibition and Congress Center, Vienna, Austria Invectys will be attending the BIO-Europe Spring 2019.…
Invectys will be attending the AACR Annual Meeting 2019, March 29 – Apr 3, 2019. Georgia World Congress Center Atlanta, The AACR (American Association for…
Invectys secures €15 million equity financing to advance lead program INVAC-1 into groundbreaking phase II clinical trial in CLL Financing complements the…
